- This case report describes one patient with metastatic lung adenocarcinoma and refractory pain from a pathologic humeral fracture, hospitalized for treatment.
- Temporary percutaneous brachial plexus peripheral nerve stimulation was placed using a dual-lead, ultrasound-guided, parallel subclavicular technique called DAVIS.
- The patient stopped all opioid use and reported substantial, sustained pain relief after implantation; no numerical pain or opioid measures are reported in the abstract.
- The authors conclude brachial plexus PNS is promising for extremity oncologic pain and that dual-lead parallel placement may help in anatomically complex or opioid-refractory cases.
Regional
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Prospective randomized trial of 80 ultrasound novices (60 medical students, 20 anesthesiology residents), with 78 completing, comparing B-mode training alone against AI-assisted nerve tracking training.
- Participants received a standardized lecture and 10-minute hands-on session, then were assessed with the AI function disabled; the AI group used the NerveTrack real-time tracking system.
- First-attempt independent identification did not differ for the median nerve (57.5% vs 65.8%, RR 1.14, 95% CI 0.81 to 1.62, p=0.452) or the brachial plexus (35.0% vs 42.1%, RR 1.20, 95% CI 0.68 to 2.11, p=0.519).
- The AI-assisted group reported higher brachial plexus confidence after additional AI-assisted training (4.7±0.5 vs 4.4±0.9, p=0.046), while the authors conclude brief AI training did not improve immediate independent identification.
- Bayesian network meta-analysis of 22 RCTs (1,699 patients) on preventing and treating rebound pain after brachial plexus block for upper-limb surgery.
- Six interventions were compared against placebo: dexamethasone, esketamine, dexmedetomidine, liposomal bupivacaine, continuous nerve block and combined nerve block.
- Versus placebo, dexamethasone (OR 0.22, 95% CI 0.11 to 0.42), dexmedetomidine (OR 0.23, 0.08 to 0.68) and continuous nerve block (OR 0.04, 0.01 to 0.33) reduced rebound pain incidence.
- Dexamethasone and continuous block lowered 12-hour pain scores, and combined block lowered 24-hour scores; the authors call the evidence exploratory and hypothesis-generating.
- Single-center, randomized, participant- and assessor-blinded, sham-controlled trial of 120 adults undergoing arthroscopic shoulder surgery with single-shot interscalene block.
- Patients received either active transcutaneous auricular vagus nerve stimulation or sham stimulation, applied perioperatively and on postoperative days 1 and 2.
- Rebound pain occurred in 20.0% of the taVNS group versus 43.3% of the sham group (absolute risk reduction 23.3%, 95% CI 7.2% to 39.5%; p=0.006).
- Secondary results showed modestly lower pain scores and better recovery and sleep, with no added adverse events; sufentanil use did not differ significantly.
- This narrative practical review synthesizes indirect pharmacological and adjacent procedural evidence, with no dedicated comparative trial of local anesthetics within RFA.
- It suggests lidocaine 1% as a default for skin and track anesthesia, and avoiding lidocaine 2% near the target nerve where stimulation testing is done, based on mechanistic reasoning.
- Across five randomized trials outside interventional pain settings, premixing lidocaine and bupivacaine showed no onset advantage over bupivacaine alone and sometimes shortened duration.
- The authors conclude these considerations are provisional and call for prospective studies, and they provide an allergy substitution pathway centered on formal allergist evaluation.
- Retrospective cohort at two affiliate hospitals (2015-2026) of eight patients with a pre-existing spinal cord stimulator, covering 12 deliveries.
- Neuraxial labor analgesia or cesarean anesthesia was attempted in every delivery, with the cohort including both successes and failures.
- A reportedly successful block was achieved in 10 cases, both failures occurred in emergencies, and no dural puncture, new deficit, LAST, ICU admission, or device complication was recorded.
- Intrapartum device status was documented in only three of 12 deliveries, so the authors conclude that peripartum device management was inconsistently documented.
- Single-patient case report of a woman in her late 20s with refractory post-traumatic chronic pain, PTSD, headaches, and occipital neuralgia after repeated traumatic brain injuries.
- She received an ultrasound-guided percutaneous temporary left vagus nerve stimulator for 60 days after conservative management failed.
- Pain fell from 10/10 to 0/10 over eight weeks, and the analgesic benefit was reported as sustained at 4-month follow-up.
- PCL-5 PTSD scores rose during follow-up, and no pre-procedure PCL-5 baseline was available to judge the overall change.
- Retrospective single-center review of 15 patients with acute fatty liver of pregnancy who had cesarean delivery between 2018 and 2026, after excluding 5 of 20 identified.
- Eleven received single-shot spinal anesthesia, one continuous spinal (for placenta accreta spectrum), and three general anesthesia (for severe disease, thrombocytopenia, or emergency indications).
- One general anesthesia patient died 16 h after delivery, and one spinal patient had postpartum encephalopathy with transient diabetes insipidus; all spinal patients recovered normal sensory and motor function.
- The authors conclude single-shot spinal anesthesia was feasible, while general anesthesia was used for more severe disease or emergency obstetric indications.
- Prospective observational cohort of 171 patients at one center undergoing spinal cord stimulation trials (2017–2021), comparing screening-based fast track with formal psychological assessment.
- Patients who screened negative on validated questionnaires and a mental health checklist went straight to trial (FT), while screen-positive patients saw a psychologist (AP).
- Trial-to-implant rates were similar (72% AP vs 70% FT, p=0.811), and 1-year responder rates were comparable (53% AP vs 60% FT, p=0.927).
- Higher baseline pain intensity and tricyclic antidepressant use were associated with implant failure, while pain duration over 10 years was associated with success; the authors conclude the tool allows bypassing routine assessment without compromising outcomes.
- Randomized, placebo-controlled, double-blinded crossover-style study in 20 healthy participants testing topical drugs on peripheral sensory nerve excitability.
- Compared topical 5% lidocaine, 10% phenytoin and 2% mepyramine against placebo, measuring perception threshold changes with a new sodium channel nociceptor testing protocol.
- Perception threshold increases differed between drugs (P < 0.01) and versus placebo (P < 0.01), except phenytoin (P = 0.22), which did not differ significantly.
- Authors report a computational model suggesting lidocaine and mepyramine alter Nav1.7, 1.8 and 1.9 currents differently, supporting the protocol for probing subtype-specific pharmacology.
- A prospective multicentre cohort at seven Dutch hospitals enrolled 103 frail patients (mean age 87) who chose non-operative management of hip fracture.
- All patients received an ultrasound-guided pericapsular nerve group block with phenol 6% (mean 10 ml), with a second needle needed in 14%; there was no comparator group.
- At 1 week, 34/36 (94%) reported acceptable pain at rest, and 24/53 (45%) could transfer from bed to chair.
- Three-month mortality was 72/91 (79%), with median survival of 9 days; the authors describe the block as an effective add-on analgesic.
- This overview reviews health economic principles and published full and partial economic evaluations of intrathecal drug delivery (ITDD) systems across cancer pain, chronic non-cancer pain, and spasticity.
- ITDD is compared with conventional management strategies, and the analyses span varying perspectives and healthcare settings.
- Most analyses suggest ITDD is cost-effective, particularly for cancer-related pain and spasticity, though the authors caution that findings rest on heterogeneous methods and often small or uncontrolled effectiveness data.
- Evidence for chronic non-cancer pain is sparse and inconsistent, and the authors call for comparative effectiveness research and long-term economic modeling.
- This case report describes one patient with prior lumbar spine surgery and refractory low back pain who had two intrathecal pump explants for suspected infection.
- The patient was ultimately diagnosed with type IV titanium hypersensitivity, and the pump was reimplanted after being encased in an expanded polytetrafluoroethylene (ePTFE) fabric pouch.
- The reimplanted intrathecal drug delivery system was reported as successful, with no rejection described.
- The authors conclude that device-component hypersensitivity should be considered in recurrent or unexplained pump site complications, and that an ePTFE pouch may allow reimplantation.
- This narrative review draws on PubMed, Google Scholar, reference lists, and intrathecal pump device manuals to cover perioperative, obstetric, and ICU care of patients with implanted intrathecal drug delivery systems.
- It is organized into five sections: intrathecal pharmacology, implantation considerations, perioperative care, neuraxial anesthesia, and device-related safety concerns.
- Where evidence is limited, the authors supplement the literature with expert opinion, so some recommendations rest on consensus rather than data.
- The authors highlight intrathecal medications, their behavior under MRI, and precautions before any neuraxial access in these patients.
- A retrospective single-center study of 53 patients with refractory cancer pain on intrathecal infusion systems, where the sequential flex mode was used after continuous mode failed.
- The sequential flex mode uses a basal flow with large boluses and was compared with the prior continuous flow rate mode in the same patients.
- 71.7% ± 6.43% of patients achieved at least 30% NRS reduction, and median NRS fell from 6.4 (SD 2.0) to 3.3 (SD 2.2), p<0.0001.
- The authors conclude the flex mode may improve pain relief and limit dose escalation, with adverse effects in 20.3% of switches, mostly non-serious increased anxiety.
- This is a historical commentary, not a primary study, tracing neuraxial therapeutics for pain over roughly the past 50 years.
- It covers the advances leading to current neuraxially targeted therapies and considers where this line of development may lead.
- The abstract reports no quantitative results, sample sizes, or comparative outcomes, so it offers a narrative overview rather than evidence of effect.
- This practical guide synthesizes evidence, consensus recommendations, and international clinical experience on intrathecal drug delivery for refractory pain.
- It covers preimplant evaluation, trialing, pump and catheter selection, perioperative care, early troubleshooting, long-term maintenance, and complication surveillance.
- It reviews intrathecal opioids, local anesthetics, ziconotide, clonidine, and baclofen, with attention to indication-specific dosing and safety, but reports no pooled quantitative results.
- It frames outcomes beyond pain intensity, including function, quality of life, and reduced systemic medication use, and addresses cancer and non-cancer populations separately.
- Retrospective single-center study of 215 patients with chronic non-cancer pain who received intrathecal drug delivery devices between 2009 and 2022, most with PSPS2 (184 patients).
- The exposure was intrathecal drug delivery, and explant reasons were compared with spinal cord stimulation explant rates from a similar patient population.
- The explant rate was 26.1%, with device-related infection the leading cause in 9.3% of patients (5.9% of device surgeries) and loss of analgesic efficacy in 5.6%.
- Infections occurred earlier after implant than other complications, and no demographic or comorbidity factors correlated with explant, per the authors.
- Single-center retrospective chart review of 441 cancer patients with intrathecal pumps, of whom 117 had two chest CTs at least 30 days apart.
- No comparator; catheter migration was defined as movement of one or more vertebral levels between the two imaging studies.
- Migration occurred in 15.4% (18 of 117), all limited to a single level; revision-requiring migration occurred in 2 of 441 (0.45%).
- The authors conclude minor migration is common but clinically significant migration is rare with their anchoring and closure techniques, and no demographic factors were associated.
- Retrospective case series of five patients with chronic pain and regionally localized pain who had implanted intrathecal devices and received bupivacaine monotherapy.
- Device duration ranged from over 2 to over 12 years, and two patients had moved from an opioid-bupivacaine combination to bupivacaine alone.
- All five patients reported at least 50% pain relief and stopped systemic opioids.
- The authors suggest monotherapy may be effective for localized pain but state that more studies are needed to establish its safety and efficacy.
- A single-center retrospective study of 31 patients, with 162 serial blood samples drawn before pump refills during intrathecal bupivacaine for cancer pain.
- Serum bupivacaine concentration was examined against daily dose and infusion flow rate, with body mass index also assessed as a factor.
- Mean serum concentration was 167.7 µg/L (SD 266.2) at a mean daily dose of 39.5 mg/day (SD 31.4), and concentration rose with dose.
- Higher flow rates stayed independently associated with concentration after adjusting for dose, and the authors conclude exposure is well below the toxicity threshold.
- This narrative review searched five databases and screened studies with three reviewers, then synthesized them descriptively due to heterogeneity.
- It examines intrathecal drug delivery systems for less common refractory pain, including spinal cord injury pain, transverse myelitis, diabetic neuropathy, postherpetic neuralgia and craniofacial pain.
- The authors found the evidence rests mainly on observational studies and small trials, with possible meaningful relief in selected patients but variable magnitude and durability of response.
- They conclude the evidence is limited, that selective clinical use may contribute to this gap, and that future research is needed to define its role.
- Retrospective single-center cohort of 435 patients with cancer pain treated with intrathecal drug delivery from 2013 to 2023; 222 met inclusion criteria.
- Longitudinal Brief Pain Inventory and Condensed Memorial Symptom Assessment Scale scores were compared before and after implantation, with no concurrent comparator group.
- Over the first 90 days, pain severity, pain interference, and physical symptom scores each declined per day (BPI-SEV -0.014, 95% CI -0.020 to -0.009; BPI-INT -0.020; CMSAS-PHYS -0.004), and 91% stopped systemic opioids.
- Scores worsened before implantation and improved afterward, and the authors report benefits sustained up to one year.
- Systematic review and meta-analysis of 39 studies (n=2652) in adults with chronic non-cancer pain treated with intrathecal drug delivery.
- Twenty single-arm comparisons contributed to the pain-intensity meta-analysis at 12 months, so there was no controlled comparator.
- Pooled pain reduction from baseline was 2.64 (95% CI 2.19 to 3.08), with a 75% probability of exceeding the 2-unit MCID (95% CI 68% to 83%).
- All studies reported functional and HRQoL improvements, but adverse event reporting was inconsistent and certainty of evidence was low.
- Cross-sectional analysis of National Inpatient Sample adult hospitalizations for rib or hip fractures from 2016 to 2022, including 298,343 rib and 462,796 hip fracture admissions.
- Compares receipt of regional analgesia by do-not-resuscitate status; regional analgesia was received in 2.9% of rib and 3.0% of hip fracture hospitalizations.
- Do-not-resuscitate status was linked to lower adjusted odds of regional analgesia for rib fractures (OR 0.76; 95% CI 0.69 to 0.83) but not hip fractures (OR 1.00; 95% CI 0.94 to 1.06).
- The association was strongest among the least frail rib fracture hospitalizations (OR 0.34; 95% CI 0.25 to 0.48), and the authors call for prospective studies to confirm the findings.
- Multicenter retrospective cohort using Epic Cosmos data from 2016 to 2025, including 38,433 adults undergoing elective below-knee amputation.
- Compared 7,430 patients who received perioperative nerve blocks with 31,003 who did not, examining phantom limb syndrome coded within 12 months.
- Phantom limb syndrome coding occurred in 18.8% versus 15.1% (absolute difference 3.7%), with Mantel-Haenszel RR 1.24 (95% CI 1.20 to 1.28) after age, sex, and race adjustment.
- The authors call the findings exploratory, possibly reflecting confounding by indication or differential surveillance, and report shorter length of stay with blocks.
- Secondary analysis of 65 gastric POCUS studies drawn from the data extraction behind a previously published ASRA Pain Medicine narrative review.
- Studies were sorted by primary purpose: 54 were population or intervention research, 9 were foundational or validation work, and 2 were clinical decision-impact studies.
- Management-change status was reported or extractable in 8 studies, and all 8 reported at least one change, with rates from 0.4% to 46%.
- The two clinical decision-impact studies reported change rates of 5.0% and 18.9%, and no included study clearly linked management change to patient-centered outcomes.
AI summary not available. Read the source abstract on PubMed.
- Randomized, participant- and assessor-blinded trial of 94 patients undergoing primary unilateral total knee arthroplasty.
- Compared a single-injection adductor canal block with perineural dexamethasone against the same block followed by a continuous adductor canal catheter infusing 0.2% ropivacaine for 50 hours.
- No significant difference in opioid use at 24-48 hours (median 30 mg vs 38.8 mg; 95% CI -22.50 to 7.00 mg; p=0.213), and PACU opioid use was also not significantly different (p=0.081).
- Catheter-associated buckling occurred in 7% of the continuous group versus 0% of the single-injection group, all transient; the authors concluded the catheter did not reduce opioid use.
- Randomized, blinded two-period crossover trial in 10 female sheep receiving ultrasound-guided sciatic nerve injections.
- Compared 200 mg ropivacaine in a poloxamer-alginate in situ-forming hydrogel against 200 mg plain ropivacaine solution.
- Hydrogel prolonged sensory block (median 60 vs 24 hours) and motor block (median 60 vs 16 hours), with lower early plasma peak (Cmax 558 vs 5101 nmol/L).
- Histopathology showed more pronounced, persistent tissue degeneration, necrosis and inflammation with the hydrogel, so the authors judged it unclear whether prolonged effect reflected sustained release or toxicity.
- Systematic review and meta-analysis of 10 randomized trials of adults undergoing spine surgery, with 655 patients in the 24-hour pain analysis.
- Perioperative intravenous lidocaine infusion was compared with placebo or standard care.
- Lidocaine reduced 24-hour pain (MD -0.83; 95% CI -1.36 to -0.30; p=0.002) and opioid consumption (MD -11.64 mg IV morphine equivalents; 95% CI -16.14 to -7.14), with high heterogeneity (I² 89%).
- A post hoc subgroup analysis found larger pain reduction after instrumented fusion or complex surgery (MD -1.23) than after decompression (MD -0.20), which the authors call hypothesis-generating.
- This educational review is a focused secondary analysis of the 65 studies from an earlier narrative review of gastric POCUS in medically complex patients.
- It examined how studies reported scans not performed, scans started but not completed, technically inadequate images, and uncertain results despite visualization.
- Of the 65 studies, 32 reported at least one indeterminate or non-interpretable exam, 24 reported none, and nine were unclear or non-numeric.
- The authors state that an indeterminate scan is non-diagnostic and should prompt reliance on the original aspiration-risk assessment or a more cautious plan.
- Prospective, nonrandomized case-control study comparing herpes zoster patients with healthy age- and sex-matched volunteers; the sample size is not stated in the abstract.
- Patients received an ultrasound-guided erector spinae plane block at the affected dermatome, with serum sampled before and after blocks.
- IL-6 and substance P/CGRP levels did not differ significantly between herpes zoster patients and controls.
- The authors report a significant post-block change (P = 0.009) in substance P and beta-endorphin, but the listed medians (24.0 and 237.8 after, 30.6 before) do not clearly match a decrease.
- A retrospective cohort of 2,660 patients with chronic pelvic pain at Pelvic Rehabilitation Medicine centers across the United States, compared at baseline and about 3 months.
- The protocol was a series of six ultrasound-guided pelvic peripheral nerve blocks and trigger point injections, evaluated without a control group.
- Pain fell 48.6% (P < 0.001), 55% reached at least 50% pain improvement, and opioid use fell 45.4%, with ED and urgent care visits down 89.4%.
- The authors conclude the protocol is associated with broad improvements and call for longer-term follow-up against a control group.
- Single-center retrospective cohort of 382 patients with thoracic subacute herpetic neuralgia, propensity-matched into 72 pairs of burst-SCS and thoracic paravertebral block recipients.
- Burst spinal cord stimulation was compared with thoracic paravertebral block on pain, breakthrough pain, touch-evoked pain, sleep, and medication use over 12 months.
- Burst-SCS showed greater VAS improvement from discharge through 12 months, higher cure rates, and lower postherpetic neuralgia incidence at 3 months, though the abstract gives no effect sizes or CIs.
- Both procedures relieved pain and improved sleep, and the authors conclude burst-SCS had more favorable outcomes, with no difference in oral morphine equivalent dose.
- Prospective, randomized, single-center trial of 90 adults (89 completed) undergoing elective laparoscopic cholecystectomy, allocated to single-injection, multi-injection, or no-block groups.
- Ultrasound-guided unilateral subcostal TAP block was given as a single injection or as multiple injections, compared with no block.
- The multi-injection group had the lowest 24-hour tramadol use and lower VAS scores at 1, 6, and 24 hours (P<0.05), with PONV-free rates of 92% vs 64% vs 52% (P=0.007).
- The authors conclude both block types gave effective analgesia, with the multi-injection technique showing superior pain control and higher patient satisfaction (P<0.001).
- Hybrid retrospective study of 175 adults with chronic neuropathic pain at one US center, plus national claims data (n = 953).
- Patients had a PNS trial, and those with at least 50% relief could receive permanent implants; outcomes were compared with baseline, not a control group.
- Mean NRS-11 pain fell from 7.2 at baseline to 1.7 at 12 months, 1.4 at 24 months, and 2.2 at 36 months (all P < 0.001), with no serious adverse events reported.
- Pain center office visits fell 54.1% in months 0-12 and 58.9% in months 13-24, with two-year cost reductions totaling $10,271.
- This health-policy analysis compares September 2025 draft Medicare LCDs for peripheral nerve injections in chronic pain with the final policies, and examines their equity implications.
- The draft policies would have limited coverage mainly to trigeminal neuralgia radiofrequency and certain corticosteroid injections, with lifetime caps; the final policies restored criteria-based coverage for several blocks.
- Four contractors published materially identical final LCDs, effective October 25, 2026, while participation in the collaborative process was reported separately from final publication.
- Pudendal, intercostal, ganglion impar, ulnar, and other peripheral-nerve procedures remain noncovered for chronic pain, and the authors highlight access implications of geographically discordant coverage.
AI summary not available. Read the source abstract on PubMed.
- Retrospective single-center analysis of a Serbian teaching hospital's 2012–2025 obstetric anesthesia training partnership; 130 anesthesiologists from 41 hospitals in five countries attended.
- The intervention was an annual or biennial one-to-two-week hands-on and didactic school covering neuraxial techniques and truncal blocks, with no comparator group.
- Neuraxial cesarean use rose from 13.8% (2011) to 79.9% (2025), a 4.7% average annual rate of change, P = 0.006; labor analgesia rose from 2.0% to 14.1%, P < 0.001.
- The authors conclude the partnership supported local training capacity and that neuraxial use increased at this center during the study period.